Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary ...
Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated ...
Collaboration brings Children’s Tumor Foundation’s deep NF1 expertise and patient and family perspectives into development of ...
Climb Bio, Inc. (Nasdaq: CLYM, “Climb Bio”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), today announced additional ...
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups ...
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen ...
Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI ...
HLX79/E-602 plus rituximab produced faster responses and a higher response rate than rituximab alone, with a safety profile ...
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to ...
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to ...
As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is pinning ...
UCB, a global biopharmaceutical company focused on severe diseases, today announced the establishment of the Emmanuel Janssen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results